Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

• Status: Active, not recruiting
• Trial end date: 2022-12-31

Summary

This phase Ib trial studies the side effects and best way to give pembrolizumab and paricalcitol with or without chemotherapy in patients with pancreatic cancer that can be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may find tumor cells and help carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and paricalcitol with or without chemotherapy before surgery may help to control the disease.

• Phase: Phase 1

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborators: Merck Sharp & Dohme Corp.; National Cancer Institute (NCI)
• Treatments: Albumin-Bound Paclitaxel; Ergocalciferols; Gemcitabine; Paclitaxel; Pembrolizumab